Conatus Pharmaceuticals Inc (Nasdaq:CNAT) and its research collaborator BioReliance,Sigma-Aldrich Corporation's (Nasdaq:SIAL) biologics and early-development services business, are presenting a poster today at the 54th Annual Meeting of the Society of Toxicology (San Diego – March 22-26, 2015). The poster, entitled "Carcinogenicity Assessment of the Pan-Caspase Inhibitor, Emricasan, in Tg.rasH2 Mice," will be available for viewing in the Exhibit Hall of the San Diego Convention Center today, Monday, March 23, 2015, from 1:00 p.m. to 4:30 p.m. PT,and the authors will be available for discussion at the poster from 1:00 p.m. to 2:45 p.m. PT. The poster is available on the Events & Presentations page in the Investor Center of the Conatus website at www.conatuspharma.com.
The poster describes previously announced results of a rigorous six-month evaluation of emricasan, Conatus' orally active, irreversible pan-caspase protease inhibitor, in the Tg.rasH2 humanized mouse model, which is highly prone to developing cancer. Tg.rasH2 mice were fed 0, 10, 25, and 75 mg/kg/day of emricasan for 26 weeks. There were no treatment related deaths or overt signs of toxicity for the duration of the study. There was no evidence of emricasan-related tumor formation in any tissue. The primary conclusion of the study, which was completed in 2012, was that emricasan did not increase the incidence of neoplastic lesions in Tg.rasH2 mice and is thus considered to have no carcinogenic potential in human.
"Because of emricasan's potent ability to reduce excessive apoptosis and inflammation, we wanted to address historical, theoretical concerns about cancer with a conclusive carcinogenicity study to supplement our extensive safety database in humans," said Conatus co-founder, Executive Vice President of Research and Chief Scientific Officer, Alfred P. Spada, Ph.D. "We are very pleased to report results from this important study, which generated solidly positive data that directly and successfully addressed the theoretical concern regarding the carcinogenic potential of emricasan." (Original Source)
Shares of Conatus Pharmaceuticals closed today at $5.92, down $0.32 or 5.13 percent. CNAT has a 1-year high of $11.74 and a 1-year low of $5.06. The stock's 50-day moving average is $6.07 and it's 200-day moving average is $6.76.
On the ratings front, Conatus has been the subject of a number of recent research reports. In a report issued on March 17, Roth Capital analyst Ed Arce resumed coverage with a Buy rating on CNAT and a price target of $15, which represents a potential upside of 139.2% from where the stock is currently trading. Separately, on March 12, Stifel Nicolaus' Stephen Willey reiterated a Buy rating on the stock and has a price target of $11.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Ed Arce and Stephen Willey have a total average return of 29.6% and 37.7% respectively. Arce has a success rate of 48.2% and is ranked #182 out of 3544 while Willey has a success rate of 69.1% and is ranked #30.
Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease.